Please wait while the formulary information is being retrieved.
Drug overview for KIMYRSA (oritavancin diphosphate):
Generic name: oritavancin diphosphate (or-IT-a-VAN-sin)
Drug class: Agents to Treat Resistant Gram Positive Organisms
Therapeutic class: Anti-Infective Agents
Oritavancin diphosphate, a lipoglycopeptide antibacterial, is a semisynthetic derivative of a naturally occurring glycopeptide.
No enhanced Uses information available for this drug.
Generic name: oritavancin diphosphate (or-IT-a-VAN-sin)
Drug class: Agents to Treat Resistant Gram Positive Organisms
Therapeutic class: Anti-Infective Agents
Oritavancin diphosphate, a lipoglycopeptide antibacterial, is a semisynthetic derivative of a naturally occurring glycopeptide.
No enhanced Uses information available for this drug.
DRUG IMAGES
No Image Available
The following indications for KIMYRSA (oritavancin diphosphate) have been approved by the FDA:
Indications:
Complicated skin and skin structure Enterococcus faecalis infection
Complicated skin and skin structure infection
Complicated skin and skin structure Staphylococcus aureus infection
Complicated skin and skin structure Streptococcus agalactiae infection
Complicated skin and skin structure Streptococcus pyogenes infection
Professional Synonyms:
Complicated bacterial skin and skin structure infection
Complicated skin and skin soft tissue Enterococcus faecalis infection
Complicated skin and skin soft tissue infection due to Streptococcus pyogenes
Complicated skin and skin soft tissue infection
Complicated skin and skin structure bacterial infection
Complicated Staphylococcus aureus skin and skin soft tissue infection
Complicated Streptococcus pyogenes skin and skin structure infection
Indications:
Complicated skin and skin structure Enterococcus faecalis infection
Complicated skin and skin structure infection
Complicated skin and skin structure Staphylococcus aureus infection
Complicated skin and skin structure Streptococcus agalactiae infection
Complicated skin and skin structure Streptococcus pyogenes infection
Professional Synonyms:
Complicated bacterial skin and skin structure infection
Complicated skin and skin soft tissue Enterococcus faecalis infection
Complicated skin and skin soft tissue infection due to Streptococcus pyogenes
Complicated skin and skin soft tissue infection
Complicated skin and skin structure bacterial infection
Complicated Staphylococcus aureus skin and skin soft tissue infection
Complicated Streptococcus pyogenes skin and skin structure infection
The following dosing information is available for KIMYRSA (oritavancin diphosphate):
Dosage of oritavancin diphosphate is expressed in terms of oritavancin.
Oritavancin diphosphate is administered by IV infusion.
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| KIMYRSA 1,200 MG VIAL | Maintenance | Adults infuse 1,200 mg by intravenous route once |
No generic dosing information available.
The following drug interaction information is available for KIMYRSA (oritavancin diphosphate):
There are 1 contraindications.
These drug combinations generally should not be dispensed or administered to the same patient. A manufacturer label warning that indicates the contraindication warrants inclusion of a drug combination in this category, regardless of clinical evidence or lack of clinical evidence to support the contraindication.
| Drug Interaction | Drug Names |
|---|---|
| Live Typhoid Vaccine/Antimicrobials SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient. MECHANISM OF ACTION: The antimicrobial may be active against the organism in the live-vaccine. Antimicrobial therapy may prevent the vaccine organism from replicating enough to trigger an immune response.(1) CLINICAL EFFECTS: Vaccination may be ineffective. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Do not give oral typhoid vaccine until 72 hours after the last dose of antimicrobial. If possible, to optimize vaccine effectiveness, do not start antibacterial drugs for 72 hours after the last dose of oral typhoid vaccine. A longer interval should be considered for long-acting antimicrobials, such as azithromycin.(3) DISCUSSION: Because antimicrobial therapy may prevent sufficient vaccine-organism replication to generate an immune response, the manufacturer of live-attenuated typhoid vaccine and the Centers for Disease Control (CDC) state that the vaccine should not be administered to patients receiving antimicrobial therapy.(1-3) |
VIVOTIF |
There are 4 severe interactions.
These drug interactions can produce serious consequences in most patients. Actions required for severe interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration scheduling, and providing additional patient monitoring. Review the full interaction monograph for more information.
| Drug Interaction | Drug Names |
|---|---|
| Atogepant/CYP3A4 Inducers SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Strong, moderate, and weak CYP3A4 inducers may increase the metabolism of atogepant by CYP3A4.(1) CLINICAL EFFECTS: The concurrent use of strong, moderate, or weak CYP3A4 inducers with atogepant may result in decreased levels and clinical effectiveness of atogepant.(1) PREDISPOSING FACTORS: Induction effects may be more likely with regular use of the inducer for longer than 1-2 weeks. PATIENT MANAGEMENT: The manufacturer of atogepant recommends that patients on concomitant strong, moderate, or weak CYP3A4 inducers receive atogepant 30 mg or 60 mg once daily for prevention of episodic migraines and avoid use of atogepant for prevention of chronic migraines.(1) Patients receiving concurrent therapy with CYP3A4 inducers and atogepant should be observed for decreased clinical effectiveness. DISCUSSION: In a study of healthy subjects, rifampin, a strong CYP3A4 inducer, decreased the area-under-curve (AUC) and maximum concentration (Cmax) of atogepant by 60% and 30%, respectively. Topiramate, a weak CYP3A4 inducer, decreased atogepant AUC and Cmax by 25% and 24%, respectively.(1) Strong CYP3A4 inducers linked to this monograph include: apalutamide, barbiturates, carbamazepine, enzalutamide, fosphenytoin, ivosidenib, lumacaftor, mitotane, phenobarbital, phenytoin, primidone, rifampin, rifapentine, and St. John's wort. Moderate CYP3A4 inducers linked to this monograph include: belzutifan, bosentan, cenobamate, dabrafenib, dipyrone, efavirenz, elagolix, etravirine, lesinurad, lorlatinib, mavacamten, mitapivat, modafinil, nafcillin, pacritinib, pexidartinib, repotrectinib, rifabutin, sotorasib, telotristat, thioridazine and tovorafenib. Weak CYP3A4 inducers linked to this monograph include: armodafinil, bexarotene, brigatinib, brivaracetam, clobazam, danshen, darolutamide, dexamethasone, dicloxacillin, echinacea, eslicarbazepine, floxacillin, garlic, genistein, ginseng, glycyrrhizin, methylprednisolone, mobocertinib, nevirapine, omaveloxolone, oritavancin, oxcarbazepine, pioglitazone, pitolisant, quercetin, relugolix, rufinamide, sarilumab, sulfinpyrazone, tazemetostat, tecovirimat, terbinafine, ticlopidine, topiramate, troglitazone, vemurafenib, vinblastine, and zanubrutinib.(1,2) |
QULIPTA |
| Fecal Microbiota Spores/Antibiotics SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Fecal microbiota spores is a suspension of live bacterial spores, which may be compromised by concurrent use of antibiotics.(1) CLINICAL EFFECTS: Antibiotics may decrease the effectiveness of fecal microbiota spores.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Antibiotics should not be used concurrently with fecal microbiota spores. Antibacterial treatment should be completed for 2 to 4 days before initiating treatment with fecal microbiota spores.(1) DISCUSSION: Antibiotics may compromise the effectiveness of fecal microbiota spores. |
VOWST |
| Erlotinib/CYP3A4 Inducers SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Inducers of CYP3A4 may induce the metabolism of erlotinib.(1) CLINICAL EFFECTS: Concurrent or recent use of a CYP3A4 inducer may result in decreased levels and effectiveness of erlotinib.(1) PREDISPOSING FACTORS: Induction effects may be more likely with regular use of the inducer for longer than 1-2 weeks. PATIENT MANAGEMENT: Avoid the concurrent use of CYP3A4 inducers in patients receiving therapy with erlotinib. Consider the use of alternative agents with less enzyme induction potential.(1) Consider increasing the dosage of erlotinib by 50 mg increments as tolerated at two week intervals (to a maximum of 450 mg) while closely monitoring the patient. The highest dosage studied with concurrent rifampin is 450 mg. If the dosage of erlotinib is increased, it will need to be decreased when the inducer is discontinued.(1) DISCUSSION: Pretreatment and concurrent therapy with rifampin increased erlotinib clearance by 3-fold and decreased the erlotinib area-under-curve (AUC) by 66% to 80%. This is equivalent to a dose of about 30 mg to 50 mg in NSCLC.(1) In a study, pretreatment with rifampin for 11 days decreased the AUC of a single 450 mg dose of erlotinib to 57.6% of the AUC observed with a single 150 mg dose of erlotinib.(1) In a case report, coadministration of phenytoin (180mg daily) and erlotinib (150mg daily) increased the phenytoin concentration from 8.2mcg/ml to 24.2mcg/ml and decreased the erlotinib concentration 12-fold (from 1.77mcg/ml to 0.15mcg/ml) and increased the erlotinib clearance by 10-fold (from 3.53 L/h to 41.7 L/h).(2) In a study, concurrent use of sorafenib (400 mg twice daily) and erlotinib (150 mg daily) decreased the concentration minimum (Cmin), concentration maximum (Cmax), and AUC of erlotinib.(3) In an animal study, concurrent use of dexamethasone and erlotinib decreased the AUC of erlotinib by 0.6-fold.(4) Strong inducers of CYP3A4 include: barbiturates, encorafenib, enzalutamide, fosphenytoin, ivosidenib, mitotane, phenobarbital, phenytoin, primidone, rifampin, and rifapentine.(5,6) Moderate inducers of CYP3A4 include: belzutifan, bosentan, cenobamate, dabrafenib, dipyrone, efavirenz, elagolix, etravirine, lesinurad, lorlatinib, mavacamten, mitapivat, modafinil, nafcillin, pacritinib, pexidartinib, repotrectinib, sotorasib, telotristat, thioridazine, and tovorafenib.(5,6) Weak inducers of CYP3A4 include: amprenavir, armodafinil, bexarotene, brigatinib, brivaracetam, clobazam, danshen, darolutamide, dicloxacillin, echinacea, eslicarbazepine, flucloxacillin, garlic, genistein, ginkgo, ginseng, glycyrrhizin, mobocertinib, nevirapine, omaveloxolone, oritavancin, oxcarbazepine, pioglitazone, pitolisant, quercetin, relugolix, rufinamide, sarilumab, sulfinpyrazone, tazemetostat, tecovirimat, terbinafine, ticlopidine, topiramate, troglitazone, vemurafenib, vinblastine, and zanubrutinib.(5,6) |
ERLOTINIB HCL, TARCEVA |
| Zuranolone/CYP3A4 Inducers SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Inducers of CYP3A4 may induce the metabolism of zuranolone.(1) CLINICAL EFFECTS: Concurrent use of a CYP3A4 inducer may result in a loss of zuranolone efficacy.(1) PREDISPOSING FACTORS: Induction effects may be more likely with regular use of the inducer for longer than 1-2 weeks. PATIENT MANAGEMENT: Avoid the concurrent use of zuranolone with CYP3A4 inducers.(1) DISCUSSION: Coadministration of zuranolone with rifampin decreased the maximum concentration (Cmax) by 0.31-fold and area-under-curve (AUC) by 0.15-fold.(1) Strong CYP3A4 inducers linked to this monograph include: apalutamide, barbiturates, carbamazepine, encorafenib, enzalutamide, fosphenytoin, ivosidenib, lumacaftor, mitotane, phenobarbital, phenytoin, primidone, rifampin, rifapentine, and St. John's wort. Moderate CYP3A4 inducers linked to this monograph include: belzutifan, bosentan, cenobamate, dabrafenib, dipyrone, efavirenz, elagolix, etravirine, lesinurad, lorlatinib, mavacamten, mitapivat, modafinil, nafcillin, pacritinib, pexidartinib, repotrectinib, rifabutin, sotorasib, telotristat ethyl, thioridazine, and tovorafenib. Weak CYP3A4 inducers linked to this monograph include: armodafinil, bexarotene, brigatinib, brivaracetam, clobazam, danshen, darolutamide, dexamethasone, dicloxacillin, echinacea, eslicarbazepine, flucloxacillin, garlic, genistein, ginseng, glycyrrhizin, methylprednisolone, mobocertinib, nevirapine, omaveloxolone, oritavancin, oxcarbazepine, pioglitazone, pitolisant, quercetin, relugolix, rufinamide, sarilumab, sulfinpyrazone, tazemetostat, tecovirimat, terbinafine, ticlopidine, topiramate, troglitazone, vemurafenib, vinblastine, and zanubrutinib.(2,3) |
ZURZUVAE |
There are 3 moderate interactions.
The clinician should assess the patient’s characteristics and take action as needed. Actions required for moderate interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration.
| Drug Interaction | Drug Names |
|---|---|
| Exemestane/Selected Moderate-Weak CYP3A4 Inducers SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: CYP3A4 inducers may induce the metabolism of exemestane.(1) CLINICAL EFFECTS: Concurrent use of a CYP3A4 inducer may result in decreased levels and effectiveness of exemestane.(1) PREDISPOSING FACTORS: Induction effects may be more likely with regular use of the inducer for longer than 1-2 weeks. PATIENT MANAGEMENT: The US manufacturer of exemestane recommends that patients receiving concurrent therapy with a strong CYP3A4 inducer receive 50 mg of exemestane daily after a meal.(1) It may be prudent to consider a dosage increase for patients receiving weaker CYP3A4 inducers. DISCUSSION: In a study in 10 healthy postmenopausal subjects, pretreatment with rifampin (a strong CYP3A4 inducer, 600 mg daily for 14 days) decreased the area-under-curve (AUC) and maximum concentration (Cmax) of a single dose of exemestane (25 mg) by 54% and 41%, respectively.(1) Strong inducers of CYP3A4 would be expected to decrease the AUC of a sensitive 3A4 substrate by 80% or more and include: carbamazepine, enzalutamide, mitotane, phenobarbital, phenytoin, rifabutin, rifampin, and St. John's wort.(1-3) Moderate inducers of CYP3A4 would be expected to decrease the AUC of a sensitive 3A4 substrate by 50-80% and include: belzutifan, bosentan, cenobamate, dabrafenib, dipyrone, efavirenz, elagolix, etravirine, lesinurad, mavacamten, mitapivat, modafinil, nafcillin, pacritinib, pexidartinib, repotrectinib, rifabutin, sotorasib, telotristat ethyl, thioridazine, and tovorafenib.(2,3) Weak inducers of CYP3A4 would be expected to decrease the AUC of a sensitive 3A4 substrate by 20-50% and include: armodafinil, bexarotene, brigatinib, brivaracetam, clobazam, danshen, darolutamide, dexamethasone, dicloxacillin, echinacea, elafibranor, enasidenib, eslicarbazepine, floxacillin, garlic, gingko, ginseng, glycyrrhizin, lorlatinib, meropenem-vaborbactam, methylprednisolone, nevirapine, omaveloxolone, oritavancin, oxcarbazepine, pioglitazone, pitolisant, quercetin, relugolix, rufinamide, sarilumab, sulfinpyrazone, suzetrigine, tazemetostat, tecovirimat, terbinafine, ticlopidine, topiramate, troglitazone, vemurafenib, vinblastine, and zanubrutinib.(2,3) |
AROMASIN, EXEMESTANE |
| Ubrogepant/Moderate and Weak CYP3A4 Inducers SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Moderate or weak CYP3A4 inducers may induce the metabolism of ubrogepant.(1) CLINICAL EFFECTS: Concurrent use of a moderate or weak CYP3A4 inducer may result in decreased levels and effectiveness of ubrogepant.(1) PREDISPOSING FACTORS: Induction effects may be more likely with regular use of the inducer for longer than 1-2 weeks. PATIENT MANAGEMENT: The manufacturer recommends a dosage adjustment of ubrogepant when coadministered with moderate or weak CYP3A4 inducers. Initial dose of ubrogepant should be 100 mg. If a second dose is needed, the dose of ubrogepant should be 100 mg.(1) DISCUSSION: Coadministration of ubrogepant with rifampin, a strong CYP3A4 inducer, resulted in an 80% reduction in ubrogepant exposure. No dedicated drug interaction studies were conducted to assess concomitant use with moderate or weak CYP3A4 inducers. Dose adjustment for concomitant use of ubrogepant with moderate or weak CYP3A4 inducers is recommended based on a conservative prediction of 50% reduction in exposure of ubrogepant.(1) Moderate inducers of CYP3A4 would be expected to decrease the AUC of a sensitive 3A4 substrate by 50-80% and include: belzutifan, bosentan, cenobamate, dabrafenib, dipyrone, efavirenz, elagolix, etravirine, lesinurad, lorlatinib, mavacamten, mitapivat, modafinil, nafcillin, pexidartinib, rifabutin, telotristat, thioridazine, and tovorafenib.(2,3) Weak inducers of CYP3A4 would be expected to decrease the AUC of a sensitive 3A4 substrate by 20-50% and include: armodafinil, bexarotene, brigatinib, brivaracetam, clobazam, danshen, dexamethasone, dicloxacillin, echinacea, elafibranor, enasidenib, eslicarbazepine, floxacillin, garlic, genistein, ginseng, glycyrrhizin, meropenem-vaborbactam, methylprednisolone, nevirapine, omaveloxolone, oritavancin, oxcarbazepine, pioglitazone, pitolisant, relugolix, repotrectinib, rufinamide, sarilumab, sulfinpyrazone,suzetrigine, tazemetostat, tecovirimat, terbinafine, ticlopidine, topiramate, troglitazone, vemurafenib, vinblastine, and zanubrutinib.(2,3) |
UBRELVY |
| Tacrolimus/Moderate and Weak CYP3A4 Inducers SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Moderate or weak CYP3A4 inducers may accelerate the metabolism of tacrolimus.(1) CLINICAL EFFECTS: Concurrent use of a moderate or weak CYP3A4 inducer may result in decreased levels and effectiveness of tacrolimus.(1) PREDISPOSING FACTORS: Induction effects may be more likely with regular use of the inducer for longer than 1-2 weeks. PATIENT MANAGEMENT: The manufacturer of tacrolimus recommends monitoring tacrolimus whole blood trough concentrations and adjusting tacrolimus dose if needed. Monitor clinical response closely.(1) DISCUSSION: A 13-year-old cystic fibrosis patient with a history of liver transplant on stable doses of tacrolimus underwent 2 separate courses of nafcillin therapy (a moderate CYP3A4 inducer). During the 1st course of nafcillin, his tacrolimus levels started to fall 3 days after starting nafcillin, became undetectable at day 8, and recovered to therapeutic levels without a change in tacrolimus dose 5 days after discontinuation of nafcillin. During the 2nd course of nafcillin, tacrolimus level became undetectable 4 days after starting nafcillin and recovered 3 days after stopping nafcillin.(2) Moderate inducers of CYP3A4 would be expected to decrease the AUC of a sensitive 3A4 substrate by 50-80% and include: belzutifan, bosentan, cenobamate, dabrafenib, dipyrone, elagolix, etravirine, lesinurad, lorlatinib, mavacamten, modafinil, nafcillin, repotrectinib, telotristat, and tovorafenib.(3,4) Weak inducers of CYP3A4 would be expected to decrease the AUC of a sensitive 3A4 substrate by 20-50% and include: armodafinil, bexarotene, brigatinib, brivaracetam, clobazam, danshen, darolutamide, dexamethasone, dicloxacillin, echinacea, elafibranor, enasidenib, eslicarbazepine, floxacillin, garlic, genistein, ginseng, glycyrrhizin, meropenem-vaborbactam, nevirapine, oritavancin, omaveloxolone, oxcarbazepine, pioglitazone, relugolix, rufinamide, sulfinpyrazone, suzetrigine, tazemetostat, tecovirimat, terbinafine, ticlopidine, topiramate, troglitazone, vinblastine, and zanubrutinib.(3,4) |
ASTAGRAF XL, ENVARSUS XR, PROGRAF, TACROLIMUS, TACROLIMUS XL |
The following contraindication information is available for KIMYRSA (oritavancin diphosphate):
Drug contraindication overview.
Oritavancin is contraindicated in patients with known hypersensitivity to the drug. Unfractionated heparin sodium is contraindicated for 48 hours after oritavancin because activated partial thromboplastin time (aPTT) is expected to remain falsely elevated for this period of time after administration of the anti-infective. (See Tests Used to Monitor Coagulation under Cautions: Warnings/Precautions.)
Oritavancin is contraindicated in patients with known hypersensitivity to the drug. Unfractionated heparin sodium is contraindicated for 48 hours after oritavancin because activated partial thromboplastin time (aPTT) is expected to remain falsely elevated for this period of time after administration of the anti-infective. (See Tests Used to Monitor Coagulation under Cautions: Warnings/Precautions.)
There are 0 contraindications.
There are 1 severe contraindications.
Adequate patient monitoring is recommended for safer drug use.
| Severe List |
|---|
| Clostridioides difficile infection |
There are 0 moderate contraindications.
The following adverse reaction information is available for KIMYRSA (oritavancin diphosphate):
Adverse reaction overview.
Adverse effects reported in 1.5% or more of patients receiving oritavancin include GI effects (i.e., diarrhea, nausea, vomiting, constipation), dizziness, headache, infusion site reactions (including phlebitis and extravasation), pruritus, urticaria, pyrexia, chills, abscess (limb or subcutaneous), cellulitis, increased AST and ALT concentrations, tachycardia, insomnia, and fatigue.
Adverse effects reported in 1.5% or more of patients receiving oritavancin include GI effects (i.e., diarrhea, nausea, vomiting, constipation), dizziness, headache, infusion site reactions (including phlebitis and extravasation), pruritus, urticaria, pyrexia, chills, abscess (limb or subcutaneous), cellulitis, increased AST and ALT concentrations, tachycardia, insomnia, and fatigue.
There are 16 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. |
Abnormal hepatic function tests Abscess Hyperbilirubinemia Hypersensitivity drug reaction Hyperuricemia Increased alanine transaminase Increased aspartate transaminase |
| Rare/Very Rare |
|---|
|
Anaphylaxis Anemia Angioedema Bronchospastic pulmonary disease Clostridioides difficile infection Eosinophilia Erythema multiforme Hypersensitivity angiitis Osteomyelitis |
There are 24 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Diarrhea Headache disorder Nausea Vomiting |
Dizziness Erythema Flushing Hypoglycemic disorder Induration of skin Injection site sequelae Myalgia Peripheral edema Phlebitis after infusion Pruritus of skin Skin rash Tachycardia Tenosynovitis Urticaria |
| Rare/Very Rare |
|---|
|
Back pain Cellulitis Chest pain Chills Tremor Wheezing |
The following precautions are available for KIMYRSA (oritavancin diphosphate):
Safety and efficacy of oritavancin have not been established in pediatric patients younger than 18 years of age.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
Category C. (See Users Guide.) There are no adequate and well-controlled studies of oritavancin in pregnant women, and the drug should be used during pregnancy only if potential benefits justify potential risks to the fetus. Reproduction studies in rats or rabbits have not revealed evidence of harm to the fetus at dosages equivalent to a human dose of 300 mg (25% of the recommend 1.2-g single dose); higher doses have not been evaluated.
Oritavancin is distributed into milk in lactating rats; it is not known whether the drug is distributed into human milk. Oritavancin should be used with caution in nursing women.
Clinical trials of oritavancin did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently than younger adults. Other clinical experience has not revealed age-related differences in response, but the possibility of greater sensitivity in some older patients cannot be ruled out.
The following prioritized warning is available for KIMYRSA (oritavancin diphosphate):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for KIMYRSA (oritavancin diphosphate)'s list of indications:
| Complicated skin and skin structure infection | |
| H00.03 | Abscess of eyelid |
| H00.031 | Abscess of right upper eyelid |
| H00.032 | Abscess of right lower eyelid |
| H00.033 | Abscess of eyelid right eye, unspecified eyelid |
| H00.034 | Abscess of left upper eyelid |
| H00.035 | Abscess of left lower eyelid |
| H00.036 | Abscess of eyelid left eye, unspecified eyelid |
| H00.039 | Abscess of eyelid unspecified eye, unspecified eyelid |
| H60.0 | Abscess of external ear |
| H60.00 | Abscess of external ear, unspecified ear |
| H60.01 | Abscess of right external ear |
| H60.02 | Abscess of left external ear |
| H60.03 | Abscess of external ear, bilateral |
| H60.1 | Cellulitis of external ear |
| H60.10 | Cellulitis of external ear, unspecified ear |
| H60.11 | Cellulitis of right external ear |
| H60.12 | Cellulitis of left external ear |
| H60.13 | Cellulitis of external ear, bilateral |
| J34.0 | Abscess, furuncle and carbuncle of nose |
| K61 | Abscess of anal and rectal regions |
| K61.0 | Anal abscess |
| K61.1 | Rectal abscess |
| K61.2 | Anorectal abscess |
| K61.3 | Ischiorectal abscess |
| K61.4 | Intrasphincteric abscess |
| L02 | Cutaneous abscess, furuncle and carbuncle |
| L02.0 | Cutaneous abscess, furuncle and carbuncle of face |
| L02.01 | Cutaneous abscess of face |
| L02.03 | Carbuncle of face |
| L02.1 | Cutaneous abscess, furuncle and carbuncle of neck |
| L02.11 | Cutaneous abscess of neck |
| L02.13 | Carbuncle of neck |
| L02.2 | Cutaneous abscess, furuncle and carbuncle of trunk |
| L02.21 | Cutaneous abscess of trunk |
| L02.211 | Cutaneous abscess of abdominal wall |
| L02.212 | Cutaneous abscess of back [any part, except buttock] |
| L02.213 | Cutaneous abscess of chest wall |
| L02.214 | Cutaneous abscess of groin |
| L02.215 | Cutaneous abscess of perineum |
| L02.216 | Cutaneous abscess of umbilicus |
| L02.219 | Cutaneous abscess of trunk, unspecified |
| L02.23 | Carbuncle of trunk |
| L02.231 | Carbuncle of abdominal wall |
| L02.232 | Carbuncle of back [any part, except buttock] |
| L02.233 | Carbuncle of chest wall |
| L02.234 | Carbuncle of groin |
| L02.235 | Carbuncle of perineum |
| L02.236 | Carbuncle of umbilicus |
| L02.239 | Carbuncle of trunk, unspecified |
| L02.3 | Cutaneous abscess, furuncle and carbuncle of buttock |
| L02.31 | Cutaneous abscess of buttock |
| L02.33 | Carbuncle of buttock |
| L02.4 | Cutaneous abscess, furuncle and carbuncle of limb |
| L02.41 | Cutaneous abscess of limb |
| L02.411 | Cutaneous abscess of right axilla |
| L02.412 | Cutaneous abscess of left axilla |
| L02.413 | Cutaneous abscess of right upper limb |
| L02.414 | Cutaneous abscess of left upper limb |
| L02.415 | Cutaneous abscess of right lower limb |
| L02.416 | Cutaneous abscess of left lower limb |
| L02.419 | Cutaneous abscess of limb, unspecified |
| L02.43 | Carbuncle of limb |
| L02.431 | Carbuncle of right axilla |
| L02.432 | Carbuncle of left axilla |
| L02.433 | Carbuncle of right upper limb |
| L02.434 | Carbuncle of left upper limb |
| L02.435 | Carbuncle of right lower limb |
| L02.436 | Carbuncle of left lower limb |
| L02.439 | Carbuncle of limb, unspecified |
| L02.5 | Cutaneous abscess, furuncle and carbuncle of hand |
| L02.51 | Cutaneous abscess of hand |
| L02.511 | Cutaneous abscess of right hand |
| L02.512 | Cutaneous abscess of left hand |
| L02.519 | Cutaneous abscess of unspecified hand |
| L02.53 | Carbuncle of hand |
| L02.531 | Carbuncle of right hand |
| L02.532 | Carbuncle of left hand |
| L02.539 | Carbuncle of unspecified hand |
| L02.6 | Cutaneous abscess, furuncle and carbuncle of foot |
| L02.61 | Cutaneous abscess of foot |
| L02.611 | Cutaneous abscess of right foot |
| L02.612 | Cutaneous abscess of left foot |
| L02.619 | Cutaneous abscess of unspecified foot |
| L02.63 | Carbuncle of foot |
| L02.631 | Carbuncle of right foot |
| L02.632 | Carbuncle of left foot |
| L02.639 | Carbuncle of unspecified foot |
| L02.8 | Cutaneous abscess, furuncle and carbuncle of other sites |
| L02.81 | Cutaneous abscess of other sites |
| L02.811 | Cutaneous abscess of head [any part, except face] |
| L02.818 | Cutaneous abscess of other sites |
| L02.83 | Carbuncle of other sites |
| L02.831 | Carbuncle of head [any part, except face] |
| L02.838 | Carbuncle of other sites |
| L02.9 | Cutaneous abscess, furuncle and carbuncle, unspecified |
| L02.91 | Cutaneous abscess, unspecified |
| L02.93 | Carbuncle, unspecified |
| L03 | Cellulitis and acute lymphangitis |
| L03.0 | Cellulitis and acute lymphangitis of finger and toe |
| L03.01 | Cellulitis of finger |
| L03.011 | Cellulitis of right finger |
| L03.012 | Cellulitis of left finger |
| L03.019 | Cellulitis of unspecified finger |
| L03.02 | Acute lymphangitis of finger |
| L03.021 | Acute lymphangitis of right finger |
| L03.022 | Acute lymphangitis of left finger |
| L03.029 | Acute lymphangitis of unspecified finger |
| L03.03 | Cellulitis of toe |
| L03.031 | Cellulitis of right toe |
| L03.032 | Cellulitis of left toe |
| L03.039 | Cellulitis of unspecified toe |
| L03.04 | Acute lymphangitis of toe |
| L03.041 | Acute lymphangitis of right toe |
| L03.042 | Acute lymphangitis of left toe |
| L03.049 | Acute lymphangitis of unspecified toe |
| L03.1 | Cellulitis and acute lymphangitis of other parts of limb |
| L03.11 | Cellulitis of other parts of limb |
| L03.111 | Cellulitis of right axilla |
| L03.112 | Cellulitis of left axilla |
| L03.113 | Cellulitis of right upper limb |
| L03.114 | Cellulitis of left upper limb |
| L03.115 | Cellulitis of right lower limb |
| L03.116 | Cellulitis of left lower limb |
| L03.119 | Cellulitis of unspecified part of limb |
| L03.12 | Acute lymphangitis of other parts of limb |
| L03.121 | Acute lymphangitis of right axilla |
| L03.122 | Acute lymphangitis of left axilla |
| L03.123 | Acute lymphangitis of right upper limb |
| L03.124 | Acute lymphangitis of left upper limb |
| L03.125 | Acute lymphangitis of right lower limb |
| L03.126 | Acute lymphangitis of left lower limb |
| L03.129 | Acute lymphangitis of unspecified part of limb |
| L03.2 | Cellulitis and acute lymphangitis of face and neck |
| L03.21 | Cellulitis and acute lymphangitis of face |
| L03.211 | Cellulitis of face |
| L03.212 | Acute lymphangitis of face |
| L03.22 | Cellulitis and acute lymphangitis of neck |
| L03.221 | Cellulitis of neck |
| L03.222 | Acute lymphangitis of neck |
| L03.3 | Cellulitis and acute lymphangitis of trunk |
| L03.31 | Cellulitis of trunk |
| L03.311 | Cellulitis of abdominal wall |
| L03.312 | Cellulitis of back [any part except buttock] |
| L03.313 | Cellulitis of chest wall |
| L03.314 | Cellulitis of groin |
| L03.315 | Cellulitis of perineum |
| L03.316 | Cellulitis of umbilicus |
| L03.317 | Cellulitis of buttock |
| L03.319 | Cellulitis of trunk, unspecified |
| L03.32 | Acute lymphangitis of trunk |
| L03.321 | Acute lymphangitis of abdominal wall |
| L03.322 | Acute lymphangitis of back [any part except buttock] |
| L03.323 | Acute lymphangitis of chest wall |
| L03.324 | Acute lymphangitis of groin |
| L03.325 | Acute lymphangitis of perineum |
| L03.326 | Acute lymphangitis of umbilicus |
| L03.327 | Acute lymphangitis of buttock |
| L03.329 | Acute lymphangitis of trunk, unspecified |
| L03.8 | Cellulitis and acute lymphangitis of other sites |
| L03.81 | Cellulitis of other sites |
| L03.811 | Cellulitis of head [any part, except face] |
| L03.818 | Cellulitis of other sites |
| L03.89 | Acute lymphangitis of other sites |
| L03.891 | Acute lymphangitis of head [any part, except face] |
| L03.898 | Acute lymphangitis of other sites |
| L03.9 | Cellulitis and acute lymphangitis, unspecified |
| L03.90 | Cellulitis, unspecified |
| L03.91 | Acute lymphangitis, unspecified |
| L05.0 | Pilonidal cyst and sinus with abscess |
| L05.01 | Pilonidal cyst with abscess |
| L05.02 | Pilonidal sinus with abscess |
| L08.0 | Pyoderma |
| L08.89 | Other specified local infections of the skin and subcutaneous tissue |
| L08.9 | Local infection of the skin and subcutaneous tissue, unspecified |
| M72.6 | Necrotizing fasciitis |
| N48.21 | Abscess of corpus cavernosum and penis |
| N48.22 | Cellulitis of corpus cavernosum and penis |
| N75.1 | Abscess of bartholin's gland |
| N76.4 | Abscess of vulva |
| N76.82 | Fournier disease of vagina and vulva |
| O91 | Infections of breast associated with pregnancy, the puerperium and lactation |
| O91.0 | Infection of nipple associated with pregnancy, the puerperium and lactation |
| O91.01 | Infection of nipple associated with pregnancy |
| O91.011 | Infection of nipple associated with pregnancy, first trimester |
| O91.012 | Infection of nipple associated with pregnancy, second trimester |
| O91.013 | Infection of nipple associated with pregnancy, third trimester |
| O91.019 | Infection of nipple associated with pregnancy, unspecified trimester |
| O91.02 | Infection of nipple associated with the puerperium |
| O91.03 | Infection of nipple associated with lactation |
| O91.1 | Abscess of breast associated with pregnancy, the puerperium and lactation |
| O91.11 | Abscess of breast associated with pregnancy |
| O91.111 | Abscess of breast associated with pregnancy, first trimester |
| O91.112 | Abscess of breast associated with pregnancy, second trimester |
| O91.113 | Abscess of breast associated with pregnancy, third trimester |
| O91.119 | Abscess of breast associated with pregnancy, unspecified trimester |
| O91.12 | Abscess of breast associated with the puerperium |
| O91.13 | Abscess of breast associated with lactation |
| Complicated skin and skin structure s. aureus infection | |
| B95.6 | Staphylococcus aureus as the cause of diseases classified elsewhere |
| B95.61 | Methicillin susceptible staphylococcus aureus infection as the cause of diseases classified elsewhere |
| B95.62 | Methicillin resistant staphylococcus aureus infection as the cause of diseases classified elsewhere |
| H00.03 | Abscess of eyelid |
| H00.031 | Abscess of right upper eyelid |
| H00.032 | Abscess of right lower eyelid |
| H00.033 | Abscess of eyelid right eye, unspecified eyelid |
| H00.034 | Abscess of left upper eyelid |
| H00.035 | Abscess of left lower eyelid |
| H00.036 | Abscess of eyelid left eye, unspecified eyelid |
| H00.039 | Abscess of eyelid unspecified eye, unspecified eyelid |
| H60.0 | Abscess of external ear |
| H60.00 | Abscess of external ear, unspecified ear |
| H60.01 | Abscess of right external ear |
| H60.02 | Abscess of left external ear |
| H60.03 | Abscess of external ear, bilateral |
| H60.1 | Cellulitis of external ear |
| H60.10 | Cellulitis of external ear, unspecified ear |
| H60.11 | Cellulitis of right external ear |
| H60.12 | Cellulitis of left external ear |
| H60.13 | Cellulitis of external ear, bilateral |
| J34.0 | Abscess, furuncle and carbuncle of nose |
| K61 | Abscess of anal and rectal regions |
| K61.0 | Anal abscess |
| K61.1 | Rectal abscess |
| K61.2 | Anorectal abscess |
| K61.3 | Ischiorectal abscess |
| K61.4 | Intrasphincteric abscess |
| L02 | Cutaneous abscess, furuncle and carbuncle |
| L02.0 | Cutaneous abscess, furuncle and carbuncle of face |
| L02.01 | Cutaneous abscess of face |
| L02.03 | Carbuncle of face |
| L02.1 | Cutaneous abscess, furuncle and carbuncle of neck |
| L02.11 | Cutaneous abscess of neck |
| L02.13 | Carbuncle of neck |
| L02.2 | Cutaneous abscess, furuncle and carbuncle of trunk |
| L02.21 | Cutaneous abscess of trunk |
| L02.211 | Cutaneous abscess of abdominal wall |
| L02.212 | Cutaneous abscess of back [any part, except buttock] |
| L02.213 | Cutaneous abscess of chest wall |
| L02.214 | Cutaneous abscess of groin |
| L02.215 | Cutaneous abscess of perineum |
| L02.216 | Cutaneous abscess of umbilicus |
| L02.219 | Cutaneous abscess of trunk, unspecified |
| L02.23 | Carbuncle of trunk |
| L02.231 | Carbuncle of abdominal wall |
| L02.232 | Carbuncle of back [any part, except buttock] |
| L02.233 | Carbuncle of chest wall |
| L02.234 | Carbuncle of groin |
| L02.235 | Carbuncle of perineum |
| L02.236 | Carbuncle of umbilicus |
| L02.239 | Carbuncle of trunk, unspecified |
| L02.3 | Cutaneous abscess, furuncle and carbuncle of buttock |
| L02.31 | Cutaneous abscess of buttock |
| L02.33 | Carbuncle of buttock |
| L02.4 | Cutaneous abscess, furuncle and carbuncle of limb |
| L02.41 | Cutaneous abscess of limb |
| L02.411 | Cutaneous abscess of right axilla |
| L02.412 | Cutaneous abscess of left axilla |
| L02.413 | Cutaneous abscess of right upper limb |
| L02.414 | Cutaneous abscess of left upper limb |
| L02.415 | Cutaneous abscess of right lower limb |
| L02.416 | Cutaneous abscess of left lower limb |
| L02.419 | Cutaneous abscess of limb, unspecified |
| L02.43 | Carbuncle of limb |
| L02.431 | Carbuncle of right axilla |
| L02.432 | Carbuncle of left axilla |
| L02.433 | Carbuncle of right upper limb |
| L02.434 | Carbuncle of left upper limb |
| L02.435 | Carbuncle of right lower limb |
| L02.436 | Carbuncle of left lower limb |
| L02.439 | Carbuncle of limb, unspecified |
| L02.5 | Cutaneous abscess, furuncle and carbuncle of hand |
| L02.51 | Cutaneous abscess of hand |
| L02.511 | Cutaneous abscess of right hand |
| L02.512 | Cutaneous abscess of left hand |
| L02.519 | Cutaneous abscess of unspecified hand |
| L02.53 | Carbuncle of hand |
| L02.531 | Carbuncle of right hand |
| L02.532 | Carbuncle of left hand |
| L02.539 | Carbuncle of unspecified hand |
| L02.6 | Cutaneous abscess, furuncle and carbuncle of foot |
| L02.61 | Cutaneous abscess of foot |
| L02.611 | Cutaneous abscess of right foot |
| L02.612 | Cutaneous abscess of left foot |
| L02.619 | Cutaneous abscess of unspecified foot |
| L02.63 | Carbuncle of foot |
| L02.631 | Carbuncle of right foot |
| L02.632 | Carbuncle of left foot |
| L02.639 | Carbuncle of unspecified foot |
| L02.8 | Cutaneous abscess, furuncle and carbuncle of other sites |
| L02.81 | Cutaneous abscess of other sites |
| L02.811 | Cutaneous abscess of head [any part, except face] |
| L02.818 | Cutaneous abscess of other sites |
| L02.83 | Carbuncle of other sites |
| L02.831 | Carbuncle of head [any part, except face] |
| L02.838 | Carbuncle of other sites |
| L02.9 | Cutaneous abscess, furuncle and carbuncle, unspecified |
| L02.91 | Cutaneous abscess, unspecified |
| L02.93 | Carbuncle, unspecified |
| L03 | Cellulitis and acute lymphangitis |
| L03.0 | Cellulitis and acute lymphangitis of finger and toe |
| L03.01 | Cellulitis of finger |
| L03.011 | Cellulitis of right finger |
| L03.012 | Cellulitis of left finger |
| L03.019 | Cellulitis of unspecified finger |
| L03.02 | Acute lymphangitis of finger |
| L03.021 | Acute lymphangitis of right finger |
| L03.022 | Acute lymphangitis of left finger |
| L03.029 | Acute lymphangitis of unspecified finger |
| L03.03 | Cellulitis of toe |
| L03.031 | Cellulitis of right toe |
| L03.032 | Cellulitis of left toe |
| L03.039 | Cellulitis of unspecified toe |
| L03.04 | Acute lymphangitis of toe |
| L03.041 | Acute lymphangitis of right toe |
| L03.042 | Acute lymphangitis of left toe |
| L03.049 | Acute lymphangitis of unspecified toe |
| L03.1 | Cellulitis and acute lymphangitis of other parts of limb |
| L03.11 | Cellulitis of other parts of limb |
| L03.111 | Cellulitis of right axilla |
| L03.112 | Cellulitis of left axilla |
| L03.113 | Cellulitis of right upper limb |
| L03.114 | Cellulitis of left upper limb |
| L03.115 | Cellulitis of right lower limb |
| L03.116 | Cellulitis of left lower limb |
| L03.119 | Cellulitis of unspecified part of limb |
| L03.12 | Acute lymphangitis of other parts of limb |
| L03.121 | Acute lymphangitis of right axilla |
| L03.122 | Acute lymphangitis of left axilla |
| L03.123 | Acute lymphangitis of right upper limb |
| L03.124 | Acute lymphangitis of left upper limb |
| L03.125 | Acute lymphangitis of right lower limb |
| L03.126 | Acute lymphangitis of left lower limb |
| L03.129 | Acute lymphangitis of unspecified part of limb |
| L03.2 | Cellulitis and acute lymphangitis of face and neck |
| L03.21 | Cellulitis and acute lymphangitis of face |
| L03.211 | Cellulitis of face |
| L03.212 | Acute lymphangitis of face |
| L03.22 | Cellulitis and acute lymphangitis of neck |
| L03.221 | Cellulitis of neck |
| L03.222 | Acute lymphangitis of neck |
| L03.3 | Cellulitis and acute lymphangitis of trunk |
| L03.31 | Cellulitis of trunk |
| L03.311 | Cellulitis of abdominal wall |
| L03.312 | Cellulitis of back [any part except buttock] |
| L03.313 | Cellulitis of chest wall |
| L03.314 | Cellulitis of groin |
| L03.315 | Cellulitis of perineum |
| L03.316 | Cellulitis of umbilicus |
| L03.317 | Cellulitis of buttock |
| L03.319 | Cellulitis of trunk, unspecified |
| L03.32 | Acute lymphangitis of trunk |
| L03.321 | Acute lymphangitis of abdominal wall |
| L03.322 | Acute lymphangitis of back [any part except buttock] |
| L03.323 | Acute lymphangitis of chest wall |
| L03.324 | Acute lymphangitis of groin |
| L03.325 | Acute lymphangitis of perineum |
| L03.326 | Acute lymphangitis of umbilicus |
| L03.327 | Acute lymphangitis of buttock |
| L03.329 | Acute lymphangitis of trunk, unspecified |
| L03.8 | Cellulitis and acute lymphangitis of other sites |
| L03.81 | Cellulitis of other sites |
| L03.811 | Cellulitis of head [any part, except face] |
| L03.818 | Cellulitis of other sites |
| L03.89 | Acute lymphangitis of other sites |
| L03.891 | Acute lymphangitis of head [any part, except face] |
| L03.898 | Acute lymphangitis of other sites |
| L03.9 | Cellulitis and acute lymphangitis, unspecified |
| L03.90 | Cellulitis, unspecified |
| L03.91 | Acute lymphangitis, unspecified |
| L05.0 | Pilonidal cyst and sinus with abscess |
| L05.01 | Pilonidal cyst with abscess |
| L05.02 | Pilonidal sinus with abscess |
| L08.0 | Pyoderma |
| M72.6 | Necrotizing fasciitis |
| N48.22 | Cellulitis of corpus cavernosum and penis |
| N75.1 | Abscess of bartholin's gland |
| N76.4 | Abscess of vulva |
| O91 | Infections of breast associated with pregnancy, the puerperium and lactation |
| O91.0 | Infection of nipple associated with pregnancy, the puerperium and lactation |
| O91.01 | Infection of nipple associated with pregnancy |
| O91.011 | Infection of nipple associated with pregnancy, first trimester |
| O91.012 | Infection of nipple associated with pregnancy, second trimester |
| O91.013 | Infection of nipple associated with pregnancy, third trimester |
| O91.019 | Infection of nipple associated with pregnancy, unspecified trimester |
| O91.02 | Infection of nipple associated with the puerperium |
| O91.03 | Infection of nipple associated with lactation |
| O91.1 | Abscess of breast associated with pregnancy, the puerperium and lactation |
| O91.11 | Abscess of breast associated with pregnancy |
| O91.111 | Abscess of breast associated with pregnancy, first trimester |
| O91.112 | Abscess of breast associated with pregnancy, second trimester |
| O91.113 | Abscess of breast associated with pregnancy, third trimester |
| O91.119 | Abscess of breast associated with pregnancy, unspecified trimester |
| O91.12 | Abscess of breast associated with the puerperium |
| O91.13 | Abscess of breast associated with lactation |
| Complicated skin structure e. faecalis infection | |
| B95.2 | Enterococcus as the cause of diseases classified elsewhere |
| H00.03 | Abscess of eyelid |
| H00.031 | Abscess of right upper eyelid |
| H00.032 | Abscess of right lower eyelid |
| H00.033 | Abscess of eyelid right eye, unspecified eyelid |
| H00.034 | Abscess of left upper eyelid |
| H00.035 | Abscess of left lower eyelid |
| H00.036 | Abscess of eyelid left eye, unspecified eyelid |
| H00.039 | Abscess of eyelid unspecified eye, unspecified eyelid |
| H60.0 | Abscess of external ear |
| H60.00 | Abscess of external ear, unspecified ear |
| H60.01 | Abscess of right external ear |
| H60.02 | Abscess of left external ear |
| H60.03 | Abscess of external ear, bilateral |
| H60.1 | Cellulitis of external ear |
| H60.10 | Cellulitis of external ear, unspecified ear |
| H60.11 | Cellulitis of right external ear |
| H60.12 | Cellulitis of left external ear |
| H60.13 | Cellulitis of external ear, bilateral |
| J34.0 | Abscess, furuncle and carbuncle of nose |
| K61 | Abscess of anal and rectal regions |
| K61.0 | Anal abscess |
| K61.1 | Rectal abscess |
| K61.2 | Anorectal abscess |
| K61.3 | Ischiorectal abscess |
| K61.4 | Intrasphincteric abscess |
| L02 | Cutaneous abscess, furuncle and carbuncle |
| L02.0 | Cutaneous abscess, furuncle and carbuncle of face |
| L02.01 | Cutaneous abscess of face |
| L02.03 | Carbuncle of face |
| L02.1 | Cutaneous abscess, furuncle and carbuncle of neck |
| L02.11 | Cutaneous abscess of neck |
| L02.13 | Carbuncle of neck |
| L02.2 | Cutaneous abscess, furuncle and carbuncle of trunk |
| L02.21 | Cutaneous abscess of trunk |
| L02.211 | Cutaneous abscess of abdominal wall |
| L02.212 | Cutaneous abscess of back [any part, except buttock] |
| L02.213 | Cutaneous abscess of chest wall |
| L02.214 | Cutaneous abscess of groin |
| L02.215 | Cutaneous abscess of perineum |
| L02.216 | Cutaneous abscess of umbilicus |
| L02.219 | Cutaneous abscess of trunk, unspecified |
| L02.23 | Carbuncle of trunk |
| L02.231 | Carbuncle of abdominal wall |
| L02.232 | Carbuncle of back [any part, except buttock] |
| L02.233 | Carbuncle of chest wall |
| L02.234 | Carbuncle of groin |
| L02.235 | Carbuncle of perineum |
| L02.236 | Carbuncle of umbilicus |
| L02.239 | Carbuncle of trunk, unspecified |
| L02.3 | Cutaneous abscess, furuncle and carbuncle of buttock |
| L02.31 | Cutaneous abscess of buttock |
| L02.33 | Carbuncle of buttock |
| L02.4 | Cutaneous abscess, furuncle and carbuncle of limb |
| L02.41 | Cutaneous abscess of limb |
| L02.411 | Cutaneous abscess of right axilla |
| L02.412 | Cutaneous abscess of left axilla |
| L02.413 | Cutaneous abscess of right upper limb |
| L02.414 | Cutaneous abscess of left upper limb |
| L02.415 | Cutaneous abscess of right lower limb |
| L02.416 | Cutaneous abscess of left lower limb |
| L02.419 | Cutaneous abscess of limb, unspecified |
| L02.43 | Carbuncle of limb |
| L02.431 | Carbuncle of right axilla |
| L02.432 | Carbuncle of left axilla |
| L02.433 | Carbuncle of right upper limb |
| L02.434 | Carbuncle of left upper limb |
| L02.435 | Carbuncle of right lower limb |
| L02.436 | Carbuncle of left lower limb |
| L02.439 | Carbuncle of limb, unspecified |
| L02.5 | Cutaneous abscess, furuncle and carbuncle of hand |
| L02.51 | Cutaneous abscess of hand |
| L02.511 | Cutaneous abscess of right hand |
| L02.512 | Cutaneous abscess of left hand |
| L02.519 | Cutaneous abscess of unspecified hand |
| L02.53 | Carbuncle of hand |
| L02.531 | Carbuncle of right hand |
| L02.532 | Carbuncle of left hand |
| L02.539 | Carbuncle of unspecified hand |
| L02.6 | Cutaneous abscess, furuncle and carbuncle of foot |
| L02.61 | Cutaneous abscess of foot |
| L02.611 | Cutaneous abscess of right foot |
| L02.612 | Cutaneous abscess of left foot |
| L02.619 | Cutaneous abscess of unspecified foot |
| L02.63 | Carbuncle of foot |
| L02.631 | Carbuncle of right foot |
| L02.632 | Carbuncle of left foot |
| L02.639 | Carbuncle of unspecified foot |
| L02.8 | Cutaneous abscess, furuncle and carbuncle of other sites |
| L02.81 | Cutaneous abscess of other sites |
| L02.811 | Cutaneous abscess of head [any part, except face] |
| L02.818 | Cutaneous abscess of other sites |
| L02.83 | Carbuncle of other sites |
| L02.831 | Carbuncle of head [any part, except face] |
| L02.838 | Carbuncle of other sites |
| L02.9 | Cutaneous abscess, furuncle and carbuncle, unspecified |
| L02.91 | Cutaneous abscess, unspecified |
| L02.93 | Carbuncle, unspecified |
| L03 | Cellulitis and acute lymphangitis |
| L03.0 | Cellulitis and acute lymphangitis of finger and toe |
| L03.01 | Cellulitis of finger |
| L03.011 | Cellulitis of right finger |
| L03.012 | Cellulitis of left finger |
| L03.019 | Cellulitis of unspecified finger |
| L03.02 | Acute lymphangitis of finger |
| L03.021 | Acute lymphangitis of right finger |
| L03.022 | Acute lymphangitis of left finger |
| L03.029 | Acute lymphangitis of unspecified finger |
| L03.03 | Cellulitis of toe |
| L03.031 | Cellulitis of right toe |
| L03.032 | Cellulitis of left toe |
| L03.039 | Cellulitis of unspecified toe |
| L03.04 | Acute lymphangitis of toe |
| L03.041 | Acute lymphangitis of right toe |
| L03.042 | Acute lymphangitis of left toe |
| L03.049 | Acute lymphangitis of unspecified toe |
| L03.1 | Cellulitis and acute lymphangitis of other parts of limb |
| L03.11 | Cellulitis of other parts of limb |
| L03.111 | Cellulitis of right axilla |
| L03.112 | Cellulitis of left axilla |
| L03.113 | Cellulitis of right upper limb |
| L03.114 | Cellulitis of left upper limb |
| L03.115 | Cellulitis of right lower limb |
| L03.116 | Cellulitis of left lower limb |
| L03.119 | Cellulitis of unspecified part of limb |
| L03.12 | Acute lymphangitis of other parts of limb |
| L03.121 | Acute lymphangitis of right axilla |
| L03.122 | Acute lymphangitis of left axilla |
| L03.123 | Acute lymphangitis of right upper limb |
| L03.124 | Acute lymphangitis of left upper limb |
| L03.125 | Acute lymphangitis of right lower limb |
| L03.126 | Acute lymphangitis of left lower limb |
| L03.129 | Acute lymphangitis of unspecified part of limb |
| L03.2 | Cellulitis and acute lymphangitis of face and neck |
| L03.21 | Cellulitis and acute lymphangitis of face |
| L03.211 | Cellulitis of face |
| L03.212 | Acute lymphangitis of face |
| L03.22 | Cellulitis and acute lymphangitis of neck |
| L03.221 | Cellulitis of neck |
| L03.222 | Acute lymphangitis of neck |
| L03.3 | Cellulitis and acute lymphangitis of trunk |
| L03.31 | Cellulitis of trunk |
| L03.311 | Cellulitis of abdominal wall |
| L03.312 | Cellulitis of back [any part except buttock] |
| L03.313 | Cellulitis of chest wall |
| L03.314 | Cellulitis of groin |
| L03.315 | Cellulitis of perineum |
| L03.316 | Cellulitis of umbilicus |
| L03.317 | Cellulitis of buttock |
| L03.319 | Cellulitis of trunk, unspecified |
| L03.32 | Acute lymphangitis of trunk |
| L03.321 | Acute lymphangitis of abdominal wall |
| L03.322 | Acute lymphangitis of back [any part except buttock] |
| L03.323 | Acute lymphangitis of chest wall |
| L03.324 | Acute lymphangitis of groin |
| L03.325 | Acute lymphangitis of perineum |
| L03.326 | Acute lymphangitis of umbilicus |
| L03.327 | Acute lymphangitis of buttock |
| L03.329 | Acute lymphangitis of trunk, unspecified |
| L03.8 | Cellulitis and acute lymphangitis of other sites |
| L03.81 | Cellulitis of other sites |
| L03.811 | Cellulitis of head [any part, except face] |
| L03.818 | Cellulitis of other sites |
| L03.89 | Acute lymphangitis of other sites |
| L03.891 | Acute lymphangitis of head [any part, except face] |
| L03.898 | Acute lymphangitis of other sites |
| L03.9 | Cellulitis and acute lymphangitis, unspecified |
| L03.90 | Cellulitis, unspecified |
| L03.91 | Acute lymphangitis, unspecified |
| L05.0 | Pilonidal cyst and sinus with abscess |
| L05.01 | Pilonidal cyst with abscess |
| L05.02 | Pilonidal sinus with abscess |
| L08.0 | Pyoderma |
| L08.89 | Other specified local infections of the skin and subcutaneous tissue |
| L08.9 | Local infection of the skin and subcutaneous tissue, unspecified |
| N48.21 | Abscess of corpus cavernosum and penis |
| N48.22 | Cellulitis of corpus cavernosum and penis |
| N75.1 | Abscess of bartholin's gland |
| N76.4 | Abscess of vulva |
| O91 | Infections of breast associated with pregnancy, the puerperium and lactation |
| O91.0 | Infection of nipple associated with pregnancy, the puerperium and lactation |
| O91.01 | Infection of nipple associated with pregnancy |
| O91.011 | Infection of nipple associated with pregnancy, first trimester |
| O91.012 | Infection of nipple associated with pregnancy, second trimester |
| O91.013 | Infection of nipple associated with pregnancy, third trimester |
| O91.019 | Infection of nipple associated with pregnancy, unspecified trimester |
| O91.02 | Infection of nipple associated with the puerperium |
| O91.03 | Infection of nipple associated with lactation |
| O91.1 | Abscess of breast associated with pregnancy, the puerperium and lactation |
| O91.11 | Abscess of breast associated with pregnancy |
| O91.111 | Abscess of breast associated with pregnancy, first trimester |
| O91.112 | Abscess of breast associated with pregnancy, second trimester |
| O91.113 | Abscess of breast associated with pregnancy, third trimester |
| O91.119 | Abscess of breast associated with pregnancy, unspecified trimester |
| O91.12 | Abscess of breast associated with the puerperium |
| O91.13 | Abscess of breast associated with lactation |
| Complicated skin structure s. agalactiae infection | |
| B95.1 | Streptococcus, group b, as the cause of diseases classified elsewhere |
| H00.03 | Abscess of eyelid |
| H00.031 | Abscess of right upper eyelid |
| H00.032 | Abscess of right lower eyelid |
| H00.033 | Abscess of eyelid right eye, unspecified eyelid |
| H00.034 | Abscess of left upper eyelid |
| H00.035 | Abscess of left lower eyelid |
| H00.036 | Abscess of eyelid left eye, unspecified eyelid |
| H00.039 | Abscess of eyelid unspecified eye, unspecified eyelid |
| H60.0 | Abscess of external ear |
| H60.00 | Abscess of external ear, unspecified ear |
| H60.01 | Abscess of right external ear |
| H60.02 | Abscess of left external ear |
| H60.03 | Abscess of external ear, bilateral |
| H60.1 | Cellulitis of external ear |
| H60.10 | Cellulitis of external ear, unspecified ear |
| H60.11 | Cellulitis of right external ear |
| H60.12 | Cellulitis of left external ear |
| H60.13 | Cellulitis of external ear, bilateral |
| J34.0 | Abscess, furuncle and carbuncle of nose |
| K61 | Abscess of anal and rectal regions |
| K61.0 | Anal abscess |
| K61.1 | Rectal abscess |
| K61.2 | Anorectal abscess |
| K61.3 | Ischiorectal abscess |
| K61.4 | Intrasphincteric abscess |
| L02 | Cutaneous abscess, furuncle and carbuncle |
| L02.0 | Cutaneous abscess, furuncle and carbuncle of face |
| L02.01 | Cutaneous abscess of face |
| L02.03 | Carbuncle of face |
| L02.1 | Cutaneous abscess, furuncle and carbuncle of neck |
| L02.11 | Cutaneous abscess of neck |
| L02.13 | Carbuncle of neck |
| L02.2 | Cutaneous abscess, furuncle and carbuncle of trunk |
| L02.21 | Cutaneous abscess of trunk |
| L02.211 | Cutaneous abscess of abdominal wall |
| L02.212 | Cutaneous abscess of back [any part, except buttock] |
| L02.213 | Cutaneous abscess of chest wall |
| L02.214 | Cutaneous abscess of groin |
| L02.215 | Cutaneous abscess of perineum |
| L02.216 | Cutaneous abscess of umbilicus |
| L02.219 | Cutaneous abscess of trunk, unspecified |
| L02.23 | Carbuncle of trunk |
| L02.231 | Carbuncle of abdominal wall |
| L02.232 | Carbuncle of back [any part, except buttock] |
| L02.233 | Carbuncle of chest wall |
| L02.234 | Carbuncle of groin |
| L02.235 | Carbuncle of perineum |
| L02.236 | Carbuncle of umbilicus |
| L02.239 | Carbuncle of trunk, unspecified |
| L02.3 | Cutaneous abscess, furuncle and carbuncle of buttock |
| L02.31 | Cutaneous abscess of buttock |
| L02.33 | Carbuncle of buttock |
| L02.4 | Cutaneous abscess, furuncle and carbuncle of limb |
| L02.41 | Cutaneous abscess of limb |
| L02.411 | Cutaneous abscess of right axilla |
| L02.412 | Cutaneous abscess of left axilla |
| L02.413 | Cutaneous abscess of right upper limb |
| L02.414 | Cutaneous abscess of left upper limb |
| L02.415 | Cutaneous abscess of right lower limb |
| L02.416 | Cutaneous abscess of left lower limb |
| L02.419 | Cutaneous abscess of limb, unspecified |
| L02.43 | Carbuncle of limb |
| L02.431 | Carbuncle of right axilla |
| L02.432 | Carbuncle of left axilla |
| L02.433 | Carbuncle of right upper limb |
| L02.434 | Carbuncle of left upper limb |
| L02.435 | Carbuncle of right lower limb |
| L02.436 | Carbuncle of left lower limb |
| L02.439 | Carbuncle of limb, unspecified |
| L02.5 | Cutaneous abscess, furuncle and carbuncle of hand |
| L02.51 | Cutaneous abscess of hand |
| L02.511 | Cutaneous abscess of right hand |
| L02.512 | Cutaneous abscess of left hand |
| L02.519 | Cutaneous abscess of unspecified hand |
| L02.53 | Carbuncle of hand |
| L02.531 | Carbuncle of right hand |
| L02.532 | Carbuncle of left hand |
| L02.539 | Carbuncle of unspecified hand |
| L02.6 | Cutaneous abscess, furuncle and carbuncle of foot |
| L02.61 | Cutaneous abscess of foot |
| L02.611 | Cutaneous abscess of right foot |
| L02.612 | Cutaneous abscess of left foot |
| L02.619 | Cutaneous abscess of unspecified foot |
| L02.63 | Carbuncle of foot |
| L02.631 | Carbuncle of right foot |
| L02.632 | Carbuncle of left foot |
| L02.639 | Carbuncle of unspecified foot |
| L02.8 | Cutaneous abscess, furuncle and carbuncle of other sites |
| L02.81 | Cutaneous abscess of other sites |
| L02.811 | Cutaneous abscess of head [any part, except face] |
| L02.818 | Cutaneous abscess of other sites |
| L02.83 | Carbuncle of other sites |
| L02.831 | Carbuncle of head [any part, except face] |
| L02.838 | Carbuncle of other sites |
| L02.9 | Cutaneous abscess, furuncle and carbuncle, unspecified |
| L02.91 | Cutaneous abscess, unspecified |
| L02.93 | Carbuncle, unspecified |
| L03 | Cellulitis and acute lymphangitis |
| L03.0 | Cellulitis and acute lymphangitis of finger and toe |
| L03.01 | Cellulitis of finger |
| L03.011 | Cellulitis of right finger |
| L03.012 | Cellulitis of left finger |
| L03.019 | Cellulitis of unspecified finger |
| L03.02 | Acute lymphangitis of finger |
| L03.021 | Acute lymphangitis of right finger |
| L03.022 | Acute lymphangitis of left finger |
| L03.029 | Acute lymphangitis of unspecified finger |
| L03.03 | Cellulitis of toe |
| L03.031 | Cellulitis of right toe |
| L03.032 | Cellulitis of left toe |
| L03.039 | Cellulitis of unspecified toe |
| L03.04 | Acute lymphangitis of toe |
| L03.041 | Acute lymphangitis of right toe |
| L03.042 | Acute lymphangitis of left toe |
| L03.049 | Acute lymphangitis of unspecified toe |
| L03.1 | Cellulitis and acute lymphangitis of other parts of limb |
| L03.11 | Cellulitis of other parts of limb |
| L03.111 | Cellulitis of right axilla |
| L03.112 | Cellulitis of left axilla |
| L03.113 | Cellulitis of right upper limb |
| L03.114 | Cellulitis of left upper limb |
| L03.115 | Cellulitis of right lower limb |
| L03.116 | Cellulitis of left lower limb |
| L03.119 | Cellulitis of unspecified part of limb |
| L03.12 | Acute lymphangitis of other parts of limb |
| L03.121 | Acute lymphangitis of right axilla |
| L03.122 | Acute lymphangitis of left axilla |
| L03.123 | Acute lymphangitis of right upper limb |
| L03.124 | Acute lymphangitis of left upper limb |
| L03.125 | Acute lymphangitis of right lower limb |
| L03.126 | Acute lymphangitis of left lower limb |
| L03.129 | Acute lymphangitis of unspecified part of limb |
| L03.2 | Cellulitis and acute lymphangitis of face and neck |
| L03.21 | Cellulitis and acute lymphangitis of face |
| L03.211 | Cellulitis of face |
| L03.212 | Acute lymphangitis of face |
| L03.22 | Cellulitis and acute lymphangitis of neck |
| L03.221 | Cellulitis of neck |
| L03.222 | Acute lymphangitis of neck |
| L03.3 | Cellulitis and acute lymphangitis of trunk |
| L03.31 | Cellulitis of trunk |
| L03.311 | Cellulitis of abdominal wall |
| L03.312 | Cellulitis of back [any part except buttock] |
| L03.313 | Cellulitis of chest wall |
| L03.314 | Cellulitis of groin |
| L03.315 | Cellulitis of perineum |
| L03.316 | Cellulitis of umbilicus |
| L03.317 | Cellulitis of buttock |
| L03.319 | Cellulitis of trunk, unspecified |
| L03.32 | Acute lymphangitis of trunk |
| L03.321 | Acute lymphangitis of abdominal wall |
| L03.322 | Acute lymphangitis of back [any part except buttock] |
| L03.323 | Acute lymphangitis of chest wall |
| L03.324 | Acute lymphangitis of groin |
| L03.325 | Acute lymphangitis of perineum |
| L03.326 | Acute lymphangitis of umbilicus |
| L03.327 | Acute lymphangitis of buttock |
| L03.329 | Acute lymphangitis of trunk, unspecified |
| L03.8 | Cellulitis and acute lymphangitis of other sites |
| L03.81 | Cellulitis of other sites |
| L03.811 | Cellulitis of head [any part, except face] |
| L03.818 | Cellulitis of other sites |
| L03.89 | Acute lymphangitis of other sites |
| L03.891 | Acute lymphangitis of head [any part, except face] |
| L03.898 | Acute lymphangitis of other sites |
| L03.9 | Cellulitis and acute lymphangitis, unspecified |
| L03.90 | Cellulitis, unspecified |
| L03.91 | Acute lymphangitis, unspecified |
| L05.0 | Pilonidal cyst and sinus with abscess |
| L05.01 | Pilonidal cyst with abscess |
| L05.02 | Pilonidal sinus with abscess |
| L08.0 | Pyoderma |
| L08.89 | Other specified local infections of the skin and subcutaneous tissue |
| N48.21 | Abscess of corpus cavernosum and penis |
| N48.22 | Cellulitis of corpus cavernosum and penis |
| N75.1 | Abscess of bartholin's gland |
| N76.4 | Abscess of vulva |
| O91 | Infections of breast associated with pregnancy, the puerperium and lactation |
| O91.0 | Infection of nipple associated with pregnancy, the puerperium and lactation |
| O91.01 | Infection of nipple associated with pregnancy |
| O91.011 | Infection of nipple associated with pregnancy, first trimester |
| O91.012 | Infection of nipple associated with pregnancy, second trimester |
| O91.013 | Infection of nipple associated with pregnancy, third trimester |
| O91.019 | Infection of nipple associated with pregnancy, unspecified trimester |
| O91.02 | Infection of nipple associated with the puerperium |
| O91.03 | Infection of nipple associated with lactation |
| O91.1 | Abscess of breast associated with pregnancy, the puerperium and lactation |
| O91.11 | Abscess of breast associated with pregnancy |
| O91.111 | Abscess of breast associated with pregnancy, first trimester |
| O91.112 | Abscess of breast associated with pregnancy, second trimester |
| O91.113 | Abscess of breast associated with pregnancy, third trimester |
| O91.119 | Abscess of breast associated with pregnancy, unspecified trimester |
| O91.12 | Abscess of breast associated with the puerperium |
| O91.13 | Abscess of breast associated with lactation |
| Complicated skin structure s. pyogenes infection | |
| B95.0 | Streptococcus, group a, as the cause of diseases classified elsewhere |
| H00.03 | Abscess of eyelid |
| H00.031 | Abscess of right upper eyelid |
| H00.032 | Abscess of right lower eyelid |
| H00.033 | Abscess of eyelid right eye, unspecified eyelid |
| H00.034 | Abscess of left upper eyelid |
| H00.035 | Abscess of left lower eyelid |
| H00.036 | Abscess of eyelid left eye, unspecified eyelid |
| H00.039 | Abscess of eyelid unspecified eye, unspecified eyelid |
| H60.0 | Abscess of external ear |
| H60.00 | Abscess of external ear, unspecified ear |
| H60.01 | Abscess of right external ear |
| H60.02 | Abscess of left external ear |
| H60.03 | Abscess of external ear, bilateral |
| J34.0 | Abscess, furuncle and carbuncle of nose |
| K61 | Abscess of anal and rectal regions |
| K61.0 | Anal abscess |
| K61.1 | Rectal abscess |
| K61.2 | Anorectal abscess |
| K61.3 | Ischiorectal abscess |
| K61.4 | Intrasphincteric abscess |
| L02 | Cutaneous abscess, furuncle and carbuncle |
| L02.0 | Cutaneous abscess, furuncle and carbuncle of face |
| L02.01 | Cutaneous abscess of face |
| L02.03 | Carbuncle of face |
| L02.1 | Cutaneous abscess, furuncle and carbuncle of neck |
| L02.11 | Cutaneous abscess of neck |
| L02.13 | Carbuncle of neck |
| L02.2 | Cutaneous abscess, furuncle and carbuncle of trunk |
| L02.21 | Cutaneous abscess of trunk |
| L02.211 | Cutaneous abscess of abdominal wall |
| L02.212 | Cutaneous abscess of back [any part, except buttock] |
| L02.213 | Cutaneous abscess of chest wall |
| L02.214 | Cutaneous abscess of groin |
| L02.215 | Cutaneous abscess of perineum |
| L02.216 | Cutaneous abscess of umbilicus |
| L02.219 | Cutaneous abscess of trunk, unspecified |
| L02.23 | Carbuncle of trunk |
| L02.231 | Carbuncle of abdominal wall |
| L02.232 | Carbuncle of back [any part, except buttock] |
| L02.233 | Carbuncle of chest wall |
| L02.234 | Carbuncle of groin |
| L02.235 | Carbuncle of perineum |
| L02.236 | Carbuncle of umbilicus |
| L02.239 | Carbuncle of trunk, unspecified |
| L02.3 | Cutaneous abscess, furuncle and carbuncle of buttock |
| L02.31 | Cutaneous abscess of buttock |
| L02.33 | Carbuncle of buttock |
| L02.4 | Cutaneous abscess, furuncle and carbuncle of limb |
| L02.41 | Cutaneous abscess of limb |
| L02.411 | Cutaneous abscess of right axilla |
| L02.412 | Cutaneous abscess of left axilla |
| L02.413 | Cutaneous abscess of right upper limb |
| L02.414 | Cutaneous abscess of left upper limb |
| L02.415 | Cutaneous abscess of right lower limb |
| L02.416 | Cutaneous abscess of left lower limb |
| L02.419 | Cutaneous abscess of limb, unspecified |
| L02.43 | Carbuncle of limb |
| L02.431 | Carbuncle of right axilla |
| L02.432 | Carbuncle of left axilla |
| L02.433 | Carbuncle of right upper limb |
| L02.434 | Carbuncle of left upper limb |
| L02.435 | Carbuncle of right lower limb |
| L02.436 | Carbuncle of left lower limb |
| L02.439 | Carbuncle of limb, unspecified |
| L02.5 | Cutaneous abscess, furuncle and carbuncle of hand |
| L02.51 | Cutaneous abscess of hand |
| L02.511 | Cutaneous abscess of right hand |
| L02.512 | Cutaneous abscess of left hand |
| L02.519 | Cutaneous abscess of unspecified hand |
| L02.53 | Carbuncle of hand |
| L02.531 | Carbuncle of right hand |
| L02.532 | Carbuncle of left hand |
| L02.539 | Carbuncle of unspecified hand |
| L02.6 | Cutaneous abscess, furuncle and carbuncle of foot |
| L02.61 | Cutaneous abscess of foot |
| L02.611 | Cutaneous abscess of right foot |
| L02.612 | Cutaneous abscess of left foot |
| L02.619 | Cutaneous abscess of unspecified foot |
| L02.63 | Carbuncle of foot |
| L02.631 | Carbuncle of right foot |
| L02.632 | Carbuncle of left foot |
| L02.639 | Carbuncle of unspecified foot |
| L02.8 | Cutaneous abscess, furuncle and carbuncle of other sites |
| L02.81 | Cutaneous abscess of other sites |
| L02.811 | Cutaneous abscess of head [any part, except face] |
| L02.818 | Cutaneous abscess of other sites |
| L02.83 | Carbuncle of other sites |
| L02.831 | Carbuncle of head [any part, except face] |
| L02.838 | Carbuncle of other sites |
| L02.9 | Cutaneous abscess, furuncle and carbuncle, unspecified |
| L02.91 | Cutaneous abscess, unspecified |
| L02.93 | Carbuncle, unspecified |
| L03 | Cellulitis and acute lymphangitis |
| L03.0 | Cellulitis and acute lymphangitis of finger and toe |
| L03.01 | Cellulitis of finger |
| L03.011 | Cellulitis of right finger |
| L03.012 | Cellulitis of left finger |
| L03.019 | Cellulitis of unspecified finger |
| L03.02 | Acute lymphangitis of finger |
| L03.021 | Acute lymphangitis of right finger |
| L03.022 | Acute lymphangitis of left finger |
| L03.029 | Acute lymphangitis of unspecified finger |
| L03.03 | Cellulitis of toe |
| L03.031 | Cellulitis of right toe |
| L03.032 | Cellulitis of left toe |
| L03.039 | Cellulitis of unspecified toe |
| L03.04 | Acute lymphangitis of toe |
| L03.041 | Acute lymphangitis of right toe |
| L03.042 | Acute lymphangitis of left toe |
| L03.049 | Acute lymphangitis of unspecified toe |
| L03.1 | Cellulitis and acute lymphangitis of other parts of limb |
| L03.11 | Cellulitis of other parts of limb |
| L03.111 | Cellulitis of right axilla |
| L03.112 | Cellulitis of left axilla |
| L03.113 | Cellulitis of right upper limb |
| L03.114 | Cellulitis of left upper limb |
| L03.115 | Cellulitis of right lower limb |
| L03.116 | Cellulitis of left lower limb |
| L03.119 | Cellulitis of unspecified part of limb |
| L03.12 | Acute lymphangitis of other parts of limb |
| L03.121 | Acute lymphangitis of right axilla |
| L03.122 | Acute lymphangitis of left axilla |
| L03.123 | Acute lymphangitis of right upper limb |
| L03.124 | Acute lymphangitis of left upper limb |
| L03.125 | Acute lymphangitis of right lower limb |
| L03.126 | Acute lymphangitis of left lower limb |
| L03.129 | Acute lymphangitis of unspecified part of limb |
| L03.2 | Cellulitis and acute lymphangitis of face and neck |
| L03.21 | Cellulitis and acute lymphangitis of face |
| L03.211 | Cellulitis of face |
| L03.212 | Acute lymphangitis of face |
| L03.22 | Cellulitis and acute lymphangitis of neck |
| L03.221 | Cellulitis of neck |
| L03.222 | Acute lymphangitis of neck |
| L03.3 | Cellulitis and acute lymphangitis of trunk |
| L03.31 | Cellulitis of trunk |
| L03.311 | Cellulitis of abdominal wall |
| L03.312 | Cellulitis of back [any part except buttock] |
| L03.313 | Cellulitis of chest wall |
| L03.314 | Cellulitis of groin |
| L03.315 | Cellulitis of perineum |
| L03.316 | Cellulitis of umbilicus |
| L03.317 | Cellulitis of buttock |
| L03.319 | Cellulitis of trunk, unspecified |
| L03.32 | Acute lymphangitis of trunk |
| L03.321 | Acute lymphangitis of abdominal wall |
| L03.322 | Acute lymphangitis of back [any part except buttock] |
| L03.323 | Acute lymphangitis of chest wall |
| L03.324 | Acute lymphangitis of groin |
| L03.325 | Acute lymphangitis of perineum |
| L03.326 | Acute lymphangitis of umbilicus |
| L03.327 | Acute lymphangitis of buttock |
| L03.329 | Acute lymphangitis of trunk, unspecified |
| L03.8 | Cellulitis and acute lymphangitis of other sites |
| L03.81 | Cellulitis of other sites |
| L03.811 | Cellulitis of head [any part, except face] |
| L03.818 | Cellulitis of other sites |
| L03.89 | Acute lymphangitis of other sites |
| L03.891 | Acute lymphangitis of head [any part, except face] |
| L03.898 | Acute lymphangitis of other sites |
| L03.9 | Cellulitis and acute lymphangitis, unspecified |
| L03.90 | Cellulitis, unspecified |
| L03.91 | Acute lymphangitis, unspecified |
| L05.0 | Pilonidal cyst and sinus with abscess |
| L05.01 | Pilonidal cyst with abscess |
| L05.02 | Pilonidal sinus with abscess |
| L08.0 | Pyoderma |
| L08.89 | Other specified local infections of the skin and subcutaneous tissue |
| L08.9 | Local infection of the skin and subcutaneous tissue, unspecified |
| M72.6 | Necrotizing fasciitis |
| N48.21 | Abscess of corpus cavernosum and penis |
| N48.22 | Cellulitis of corpus cavernosum and penis |
| N75.1 | Abscess of bartholin's gland |
| N76.4 | Abscess of vulva |
| O91 | Infections of breast associated with pregnancy, the puerperium and lactation |
| O91.0 | Infection of nipple associated with pregnancy, the puerperium and lactation |
| O91.01 | Infection of nipple associated with pregnancy |
| O91.011 | Infection of nipple associated with pregnancy, first trimester |
| O91.012 | Infection of nipple associated with pregnancy, second trimester |
| O91.013 | Infection of nipple associated with pregnancy, third trimester |
| O91.019 | Infection of nipple associated with pregnancy, unspecified trimester |
| O91.02 | Infection of nipple associated with the puerperium |
| O91.03 | Infection of nipple associated with lactation |
| O91.1 | Abscess of breast associated with pregnancy, the puerperium and lactation |
| O91.11 | Abscess of breast associated with pregnancy |
| O91.111 | Abscess of breast associated with pregnancy, first trimester |
| O91.112 | Abscess of breast associated with pregnancy, second trimester |
| O91.113 | Abscess of breast associated with pregnancy, third trimester |
| O91.119 | Abscess of breast associated with pregnancy, unspecified trimester |
| O91.12 | Abscess of breast associated with the puerperium |
| O91.13 | Abscess of breast associated with lactation |
Formulary Reference Tool